[Rituximab for treatment of Felty’s syndrome]

Area of Science:

• Rheumatology
• Immunology
• Hematology

Background:

• Felty's syndrome is a rare, severe form of seropositive rheumatoid arthritis.
• Characterized by neutropenia and splenomegaly, it carries a poor prognosis due to infection risk.

Observation:

• A patient with refractory Felty's syndrome was treated with rituximab.
• The patient experienced a sustained normalization of neutrophil counts.

Findings:

• Rituximab induced remission in refractory Felty's syndrome.
• Repeated rituximab infusions were required for sustained remission and neutrophil count normalization.

Implications:

• Rituximab represents a potential therapeutic option for difficult-to-treat Felty's syndrome.
• Understanding the long-term efficacy and optimal dosing of rituximab is crucial for managing this condition.